Table 1 Clinical characteristics of 170 patients with AL-CA in this study
From: A real-world study on diagnosis and prognosis of light-chain cardiac amyloidosis in Southern China
AL-CA (n = 170) | |
|---|---|
Male, n (%) | 120 (70.59%) |
Age at diagnosis, years | 60.81 (10.46) |
Previous misdiagnosis, n (%) | 56 (32.9%) |
Patients of referred, n (%) | 92 (54.1%) |
Length of hospital stay, days | 15.94 (9.35) |
First chief complaint, n (%) | |
Dyspnea | 90 (52.94%) |
Edema in lower limbs | 38 (22.35%) |
Fatigue | 14 (8.24%) |
Others | 28 (16.47%) |
Department of first diagnosis, n (%) | |
Cardiology | 110 (64.71%) |
Nephrology | 24 (14.12%) |
Hematology | 20 (11.76%) |
Others | 16 (9.41%) |
NYHA, n (%) | |
I | 7 (4.12%) |
II | 33 (19.41%) |
III | 74 (43.53%) |
IV | 56 (32.94%) |
Mayo AL 2004 stage, n (%) | |
I | 6(4.0%) |
II | 38(25.3%) |
IIIa | 51(34%) |
IIIb | 55(36.7%) |
Comorbidities, n (%) | |
Multiple myeloma | 58 (34.12%) |
Polyserositis | 115 (67.65%) |
CHD | 35(20.59%) |
Subclinical or clinical hypothyroidism | 44 (25.88%) |
Peripheral neuropathy | 46(27.1%) |
Previous hypertension | 58 (34.12%) |
Hyperlipidemia | 41 (24.12%) |
Type 2 diabetes | 22 (12.94%) |
COPD | 19 (11.18%) |
CKD | 56 (32.94%) |
Stroke | 12 (7.06%) |
SBP, mmHg | 114.23 (24.18) |
DBP, mmHg | 71.18 (12.50) |
Pulse, Times/min | 82.41 (17.82) |
BMI, kg /m2 | 22.5 (3.5) |
Death in hospital, n (%) | 21 (12.4%) |
Assistant examination methods, n (%) | |
Non-invasive, n (%) | |
CMR | 88 (51.7%) |
SPECT | 17 (10.0%) |
Biopsy, n (%) | |
Endocardial | 21 (12.3%) |
Bone marrow | 134(78.9%) |
Renal | 13(7.6%) |
Subcutaneous fat | 89(52.4%) |
Gastrointestinal | 7(4.1%) |
Othersa | 2(1.2%) |
Treatment | |
Pacemaker | 14 (8.2%) |
ACEI/ARB | 40 (23.5%) |
Beta-blockers | 35 (20.6%) |
Loop diuretics | 154 (90.6%) |
Antisterone | 127 (74.7%) |
Tolvaptan | 15 (8.8%) |
LMWH | 29 (17.1%) |
Warfarin | 12 (7.1%) |
Digitalis | 32 (18.8%) |
Aspirin | 38 (22.4%) |
Clopidogrel | 28 (16.5%) |
Statins | 62 (36.5%) |
Chemotherapy, n (%) | 64 (37.6%) |
B + D | 39 (22.9%) |
Melphalan-based | 7 (4.1%) |
ThD/LeD | 56 (32.9%) |
ASCT | 2(1.2%) |
Palliative care, n (%) | 106(62.4%) |